Webinar
22 Oct.

Emerging trends in the expanded use of RWE across the life sciences industry

Where is the industry going?

Thursday, 10:00 a.m.  ET
Event language: English

Real-world evidence (RWE) has the potential to transform how medicines are discovered, developed, commercialized and reimbursed. Given the opportunity RWE presents, it is now being viewed as a highly strategic capability for the life sciences industry.

Watch now

This Interactive panel discussion featuring leaders from across the life sciences industry will discuss emerging trends in the use of RWE, challenges in realizing the full potential, technology trends and strategic investments.

SPEAKERS:

  • Jeffrey Morgan, Managing Director, Life Sciences, Deloitte
  • Nirosha Mahendraratnam Lederer, PhD, MSPH, Managing Associate, Real World Evidence, Duke-Margolis Center for Health Policy, Duke University
  • Christopher P. Boone, PhD, FACHE, FHIMSS, Vice President, Global Head of Health Economics and Outcomes Research, AbbVie
  • Patrick Loerch, Senior Vice President, Data Science and Biometrics, Gilead

Recommended for you

RWE focus is shifting to R&D, early investments begin to payoff

21 Sep 2022
Companies that have invested in mature RWE capabilities are seeing returns; others are behind. Results from Deloitte’s third RWE benchmarking study reveal how companies still building their capabilities can catch up.

ConvergeHEALTH Miner – Data and Analytics at Scale in Life Sciences | Deloitte US

ConvergeHEALTH MinerTM  is designed to meet the growing demands for data, insights, and evidence across the entire product life cycle.
Thursday, 22 Oct 2020 10:00 a.m. ET
Share Share event on social
Watch now